Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORETo address increasing patient cost for drugs, policy makers have been particularly focused on the increasing cost-sharing burden on patients for more expensive specialty therapies. The Affordable Care Act established an annual maximum out-of-pocket cost limit for patients enrolled in non-grandfathered plans, indicating that this issue is recognized by the federal government. Some states have also enacted polices that seek to limit prescription drug cost-sharing for patients.
In this white paper, IQVIA examines the effects of such policies on patient costs, by investigating the policies implemented in Louisiana, California, and Colorado. These three states provide an opportunity to compare states with similar policies—Louisiana and California—to a state with a much different policy— Colorado. IQVIA’s US Market Access Strategy Consulting team is uniquely suited to measure the impact of such policies thanks to longitudinal claims data and experience analyzing patient cost-sharing trends.